First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum
Ethics approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Northwest and Central Switzerland (01.03.2022, No: 2022-00162).
Consent to participate
Informed consent was obtained from the patient before the inclusion into the study. The patient gave written informed consent to anonymously use their clinical and imaging data for publication.
Competing interests
CM, RS, NM, MF and DW are listed as inventors on patent application US 2023/0165981, which contains [161Tb]Tb-DOTA-LM3. PB is a co-founder of Theravision AB.
Clinical trial registration
This study is registered with ClinicalTrials.gov (NCT05359146).
留言 (0)